HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Lupin gets EIR from USFDA for Inhalation Research Center in Florida
Mar-30-2020
Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Inhalation Research Center located at Coral Springs, Florida. The facility was inspected by the USFDA, between February 19, 2020 and February 26, 2020, on behalf of the U.K. MHRA for Lupin’s generic Fostair application to the U.K. MHRA.

Lupin’s Inhalation Research Center at Coral Springs, Florida, inaugurated in August 2015, focuses on research and development of respiratory products for the treatment of asthma, chronic obstructive pulmonary diseases and other respiratory ailments.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
  RELATED NEWS >>